Skip to main content
. 2020 Jul 8;13(10):100823. doi: 10.1016/j.tranon.2020.100823

Fig. 5.

Fig. 5

Effect of tumor rechallenge and immune cell depletion on the protective properties of the nanoimmunotherapy. (A) Effect of rechallenge with 1 million Neuro2a cells in untreated mice (naïve, gray), and long-term surviving nanoimmunotherapies-treated mice; PBNP-PTT + aCTLA-4 (rechallenged, pink), and CpG-PBNP-PTT + aCTLA-4 (rechallenged, purple). The Kaplan-Meier survival plots show complete tumor rejection and significantly higher long-term survival in the rechallenged groups compared to naïve mice (* significant difference compared to naïve mice, p < 0.05, n ≥3/group). (B–H) Immune cell depletion show importance of CD4+ and CD8+ T cells on treatment effectiveness. (B) Kaplan-Meier survival plots of neuroblastoma-bearing mice depleted in CD4+ T cells, CD8+ T cells, and NK1.1+ cells. Depletion of these immune cell types (n = 5/group) effectively abrogated the therapeutic responses of the nanoimmunotherapy. (C–H) Primary and secondary tumor growth curves for individual mice in the various treatment groups: (C, F) CD8+ T cells depleted, (D, G) CD4+ T cells depleted, (E, H) NK1.1+ depleted. Each line represents tumor growth measured in one mouse. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)